4D Molecular Therapeutics, Inc.
FDMT
$10.45
$0.111.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -454.49% | 134.10% | -4.06% | -13.94% | 3.42% |
| Total Depreciation and Amortization | 3.79% | -1.15% | 6.09% | 7.64% | -1.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.62% | 30.89% | -11.25% | -32.45% | -1.93% |
| Change in Net Operating Assets | -272.45% | -44.89% | -10.56% | 177.94% | -92.87% |
| Cash from Operations | -338.61% | 161.40% | -7.20% | 9.17% | -4.13% |
| Capital Expenditure | -- | -23.08% | 237.88% | 89.54% | 33.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 153.43% | -828.88% | 228.30% | -142.32% | 306.83% |
| Cash from Investing | 153.46% | -824.76% | 228.34% | -143.36% | 352.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.74% | 96,436.21% | -86.54% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.74% | 96,436.21% | -86.54% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.80% | 140.85% | 49.25% | -256.53% | 58.62% |